Qiagen에 대한 매도 수량은 투자자에게 Qiagen의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Qiagen (NYSE:QGEN) 주식, 공매도 수량 보고

Qiagen

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).

Qiagen NV

Qiagen N.V.

Analyst Color

Earnings

Equities

Large Cap

Mid Cap

Tech

ETFs

AMGN

AVGO

AZEK

DELL

Janus Henderson Group plc Ordinary Shares

KVYO

MNDY

NVDA

QGEN

SNOW

TOST

UPST

3분기 실적 시즌이 다가오면서, 골드만삭스는 투자자들이 재무 실적을 통해 수익을 올릴 수 있는 주요 주식 기회를 식별한 노트를 발표했다. 애널리스트 존 마샬(John Marshall)과 그의 팀은 목요일에 18개의 주식이 실적 상향 조정의 혜택을 받을 가능성이 있고, 7개의 주식은 하향 조정의 영향을 받을 가능성이 있다고 강조했다.

이번 실적 시즌에는 매수할 주식 18개, 매도할 주식 7개: 골드만삭스는 올해를 &#39;주식 선택자의 해&#39;

QIAGEN ORD

News

QIAGEN Gains FDA Clearance For Rapid QIAstat-Dx Meningitis/Encephalitis Panel, Boosting Emergency Diagnostics

QIAGEN Secures FDA Clearance For Qiastat-Dx Mini Panel, Enhancing Precision In Outpatient Respiratory Care

HSBC analyst Shubhangi Gupta downgrades Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Buy to Hold.

Downgrades

Analyst Ratings

HSBC Downgrades Qiagen to Hold

As the third-quarter earnings season approaches, Goldman Sachs has issued a note identifying key stock opportunities for investors looking to profit <a href="https://www.benzinga.com/news/earnings/24/10/41255250/banks-gear-up-for-earnings-season-15-top-stock-picks-including-citigroup-morgan-stanley-and-truist">from financial results.</a>
Analyst John Marshall and his team shared their insights on Thursday, highlighting 18 stocks that could benefit from upward earnings revisions and seven stocks likely to face downward revisions.
<h3 class="wp-block-heading">The &#8216;Stock Picker&#8217;s Year&#8217;: 10% Upside In S&amp;P 500</h3>
Goldman Sachs analysts call 2024 "the year of the stock picker," emphasizing the importance of selective investing in a volatile earnings environment.
According to the investment bank&#8217;s latest projections, the average S&amp;P 500 stock could see a 10% upside over the next 12 months. 
"We see relief rally potential," Marshall stated in his note. "Directional positioning in the options market is balanced, a much better set-up than this time last quarter."
The analysts also observed that activity in options markets, both from hedge funds and retail traders, has decreased recently, signaling a "wait-and-see" approach as investors prepare for third-quarter earnings reports and the upcoming U.S. elections.
<h3 class="wp-block-heading">Earnings Season Volatility Remains Elevated</h3>
Goldman Sachs highlighted that single-stock volatility surrounding earnings events remains at a 14-year high. 
This trend, driven by critical market debates on topics like artificial intelligence, interest rates, and the upcoming election, is expected to continue through the remainder of the year.
&#8220;We expect earnings day moves to remain elevated as most of the key debates for the market have winners and losers in the equity space,&#8221; the note added. 
With this heightened volatility, the firm continues to recommend options-based strategies, advising investors to consider buying options ahead of earnings events and selling options between earnings periods to capitalize on price movements.
<h3 class="wp-block-heading">18 Stocks Goldman Sachs Is Bullish On For Third-Quarter Earnings</h3>
Goldman Sachs&#8217; analysts have identified 18 stocks they believe are primed for upside as earnings revisions could be favorable. These stocks span a variety of sectors, from energy and financials to healthcare and technology.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Earnings Date (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gap Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>)</td>
<td>Discretionary</td>
<td>Nov. 15</td>
</tr>
<tr>
<td>Permian Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PR#NYSE">PR</a>)</td>
<td>Energy</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</td>
<td>Financials</td>
<td>Oct. 15</td>
</tr>
<tr>
<td>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>)</td>
<td>Financials</td>
<td>Oct. 16</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>Healthcare</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>Boston Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSX#NYSE">BSX</a>)</td>
<td>Healthcare</td>
<td>Oct. 23</td>
</tr>
<tr>
<td>Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>Healthcare</td>
<td>Oct. 31</td>
</tr>
<tr>
<td>Qiagen NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>)</td>
<td>Healthcare</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>AZEK Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>)</td>
<td>Industrials</td>
<td>Nov. 29</td>
</tr>
<tr>
<td>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>)</td>
<td>TMT</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>)</td>
<td>TMT</td>
<td>Dec. 6</td>
</tr>
<tr>
<td>Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>)</td>
<td>TMT</td>
<td>Nov. 25</td>
</tr>
<tr>
<td>Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>)</td>
<td>TMT</td>
<td>Nov. 13</td>
</tr>
<tr>
<td>Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)</td>
<td>TMT</td>
<td>Nov. 21</td>
</tr>
<tr>
<td>Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>)</td>
<td>TMT</td>
<td>Nov. 29</td>
</tr>
<tr>
<td>Toast Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>)</td>
<td>Utilities</td>
<td>Nov. 4</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">7 Stocks Goldman Sachs Is Bearish On For Third-Quarter Earnings</h3>
In contrast, the investment bank has identified seven stocks that they expect to face downward earnings revisions in the third quarter, advising investors to exercise caution.
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Company</th>
<th>Sector</th>
<th>Earnings Date (e)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choice Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHH#NYSE">CHH</a>)</td>
<td>Discretionary</td>
<td>Nov. 7</td>
</tr>
<tr>
<td>Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CQP#NYSE">CQP</a>)</td>
<td>Energy</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Janus Henderson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>)</td>
<td>Financials</td>
<td>Oct. 31</td>
</tr>
<tr>
<td>LyondellBasell (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYB#NYSE">LYB</a>)</td>
<td>Materials</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>)</td>
<td>Staples</td>
<td>Nov. 1</td>
</tr>
<tr>
<td>Kraft Heinz Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>)</td>
<td>Staples</td>
<td>Oct. 30</td>
</tr>
<tr>
<td>Upstart Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>)</td>
<td>TMT</td>
<td>Nov. 7</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41278012/feds-goolsbee-downplays-inflation-uptick-economists-hold-steady-on-november-rate-in">Fed&#8217;s Goolsbee Downplays Inflation Uptick, Economists Hold Steady On November Rate Interest Rate Cut Call</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

18 Stocks To Buy, 7 To Sell This Earnings Season: Goldman Sachs Calls It 'The Year Of The Stock Picker'

These updates &ndash; designed for use on the QIAsymphony and EZ2 Connect instruments &ndash; are designed to enable research and molecular diagnostics laboratories to efficiently improve results when processing larger sample volumes that are crucial for oncology research and diagnostics.
The upgrades add to the PAXgene Urine Liquid Biopsy Set recently launched by PreAnalytiX, QIAGEN&#39;s joint venture with BD. The new set, which will be commercialized by QIAGEN, enables reliable analysis of cfDNA from urine more than ever before.

QIAGEN Reveals Key Updates To Its Sample Technologies Solutions For Non-Invasive Liquid Biopsy Applications

QIAGEN N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA)))) today announced the launch of the QIAcuityDx Digital PCR System, a pivotal addition to its digital PCR portfolio now expanding into clinical diagnostics. The instrument and accessories are 510(k) exempt in the U.S. and IVDR-certified for diagnostic use in Europe.
QIAcuityDx streamlines clinical testing by providing highly precise, absolute quantitation of target DNA and RNA, supporting applications with less invasive liquid biopsies. These capabilities make it an ideal tool for monitoring cancer progression, complementing routine cancer diagnoses, which are typically performed using Next Generation Sequencing (NGS).
QIAGEN is rapidly expanding the application menu available on QIAcuityDx-System, with a new BCR::ABL assay for oncohematology planned for FDA submission in 2025. The platform also provides immediate access to QIAGEN's full portfolio of research-use products and applications via its GeneGlobe platform. QIAGEN has already signed three partnerships with pharmaceutical companies to develop companion diagnostics on the QIAcuityDx, moving digital PCR into precision medicine. In addition, QIAGEN plans to further enhance the future assay portfolio by collaborating with third parties, who will develop their own assays for the platform.

Biotech

General

QIAGEN Launches QIAcuityDx Digital PCR System For Clinical Testing In Oncology

QIAGEN Receives European IVDR Certification For QIAstat-Dx Syndromic Testing Instruments And Assays

QIAGEN And BD Joint Venture, PreAnalytiX, Launches Solution For Liquid Biopsy From Urine Samples

The multi-year agreement between QIAGEN&#39;s subsidiary Verogen and Bode extends the long-standing partnership of two leading companies in forensic investigative genetic genealogy (FIGG) to further accelerate the use of GEDmatch PRO in law enforcement and identification of human remains.&nbsp;
As part of the partnership, Bode will manage all commercial transactions for GEDmatch PRO globally, while QIAGEN will continue to develop new features with input from Bode&#39;s genealogy experts. Bode will maintain the highest level of data security as GEDmatch PRO users will continue to own their case data and no additional identifying information will be shared with Bode.

QIAGEN, Bode Technology Enter Multi-year Agreement For GEDmatch PRO Genealogy Database

QIAGEN Expands QIAcuity Digital PCR Offering With Over 100 New Assays Via GeneGlobe Platform, Supporting Cancer Research, Genetic Disorders, Infectious Disease Surveillance, And Environmental Monitoring

QIAGEN N.V.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qgen#NYSE">QGEN</a>) announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, a leading vaccines and diagnostics supplier to the Brazilian Ministry of Health. Initiated in 2009, the expanded collaboration allows Bio-Manguinhos to launch an advanced PCR (Polymerase Chain Reaction)-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus, a capability previously unavailable in Brazil&#39;s blood donation program. The recent development will also support epidemiological surveillance of Brazil&#39;s ongoing dengue epidemic by composing dengue molecular kits based on unique collaborative chemistry.
Following the news, shares of QGEN declined 0.6% to $45.57 at yesterday&#39;s close. However, the company is accelerating the introduction of cutting-edge products and capabilities to the market through tailored OEM (Original Equipment Manufacturer) offerings and extensive support for companies in the life sciences research, biotechnology and diagnostics sectors. Hence, we expect the market sentiment to remain positive around this news.
<h2>More on QIAGEN&#39;s Expanded Collaboration</h2>
Brazil&#39;s national blood screening program was launched in 2010, the largest blood donation safety initiative in its history. The advanced Brazilian Nucleic Acid Test (NAT Plus) platform, which utilizes QIAGEN&#39;s PCR reagents, was recently rolled out as part of the program. The latest advancement improves transfusional safety by detecting malaria and closing the &quot;diagnostic window&quot; between the time of infection and laboratory diagnosis. Since 2009, QIAGEN and Bio-Manguinhos have been partnering to equip the national blood screening program with advanced molecular testing solutions.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/77/77671.jpg?v=403415906" />
Image Source: Zacks Investment Research
Presently, the NAT Plus platform is operational in 30 laboratories and is critical to safeguarding blood supplies in regions where these diseases are not endemic. It supports health surveillance within the blood transfusion system, engaging over 300 trained professionals across 14 chemotherapy centers and processing 3.5 million samples annually. QIAGEN will supply critical molecular biology technologies, custom solutions and comprehensive training to facilitate Brazil&#39;s public health initiative. Under the terms of this agreement, the company&#39;s solutions will be included in the screening kits and private labeled under the Bio-Manguinhos&#39; brand.
The collaboration also emphasizes the pivotal role of QIAGEN&#39;s Strategic Partnerships and OEM Division, supporting more than 400 partners globally.
<h2>Industry Prospects Favoring QGEN</h2>
A report from the SkyQuest Technology Group valued the global PCR molecular diagnostics market at $17.8 billion in 2021, forecasted to witness a compound annual growth rate of 12.8% through 2030. The market is a fast-growing sector, driven by the need for accurate and timely diagnostic testing. The rising incidences of infectious diseases, genetic disorders and cancer create a substantial market opportunity for PCR molecular diagnostics. Furthermore, the growing awareness and adoption of precision medicine approaches further contribute to the market&#39;s potential for targeted therapies and personalized treatment regimens.
<h2>QIAGEN&#39;s Recent Developments</h2>
Last week, QIAGEN teamed up with Eli Lilly and Company to support the development of a QIAstat-Dx in-vitro diagnostic to detect APOE (apolipoprotein E) genotypes in the diagnosis of Alzheimer&#39;s disease. The panel will be integrated with QIAGEN&#39;s multiplex testing platform QIAstat-Dx, marking the first publicly disclosed collaboration for a clinical application of the system in neurodegenerative diseases and adding to two more collaborations for diagnostics development programs with other companies.
<h2>QGEN&#39;s Price Performance</h2>
In the past year, QGEN shares have gained 6% against the industry&#39;s 2.2% fall.
<h2>QGEN&#39;s Zacks Rank and Key Picks</h2>
QIAGEN currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Boston Scientific (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>), AxoGen (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/axgn#NASDAQ">AXGN</a>) and SiBone (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sibn#NASDAQ">SIBN</a>), each carrying a Zacks Rank #2 (Buy) at present.
Boston Scientific&#39;s shares have gained 58.4% in the past year. Estimates for the company&#39;s earnings per share have remained constant at $2.40 in 2024 and $2.71 in 2025 in the past 30 days. BSX&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.2%. In the last reported quarter, it posted an earnings surprise of 6.9%.
Estimates for AxoGen&#39;s 2024 loss per share have remained constant at 1 cent in the past 30 days. Shares of the company have surged 145% in the past year compared with the industry&#39;s growth of 15.5%. AXGN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 96.5%. In the last reported quarter, it delivered an earnings surprise of 200%.
Estimates for SiBone&#39;s 2024 loss per share have remained constant at 89 cents in the past 30 days. Shares of the company have dropped 30.4% in the past year against the industry&#39;s 15.5% growth. SIBN&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.4%. In the last reported quarter, it delivered an earnings surprise of 15.4%.
<a href="https://www.zacks.com/stock/news/2335917/can-qgen-stock-gain-from-the-expanded-bio-manguinhos-fiocruz-alliance?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2335917">To read this article on Zacks.com click here.</a>

Earnings Beats

Offerings

Small Cap

Markets

Trading Ideas

AXGN

SIBN

Can QGEN Stock Gain From the Expanded Bio-Manguinhos/Fiocruz Alliance?

The partnership, initiated in 2009, supported Bio-Manguinhos/Fiocruz with reagents and instruments for testing samples for HIV and hepatitis C virus.&nbsp;
With the expansion of this collaboration, Bio-Manguinhos is now able to launch an advanced PCR-based molecular screening platform to detect malaria alongside HIV, hepatitis B and C virus (HCV and HBV), a capability previously unavailable in Brazil&#39;s blood donation program. It also supports epidemiological surveillance of Brazil&#39;s ongoing dengue epidemic by composing Bio-Manguinhos/Fiocruz dengue&nbsp;molecular kits based on unique chemistry developed by QIAGEN and Bio-Manguinhos/Fiocruz. QIAGEN will supply critical molecular biology technologies, custom solutions, and comprehensive training to facilitate Brazil&#39;s public health initiative.

QIAGEN Expands Strategic Partnership With Bio-Manguinhos/Fiocruz

This collaboration represents a significant milestone as the QIAstat-Dx panel would be the first commercially available IVD for APOE genotyping.

QIAGEN Enters Collaboration With Eli Lilly To Support Development Of QIAstat-Dx In-vitro Diagnostic To Detect APOE Genotypes Which Can Play Role In Diagnosis Of Alzheimer's Disease; No Terms Disclosed

QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA)))) today announced the expansion of its Master Collaboration Agreement with AstraZeneca to develop and commercialize companion diagnostics (CDx) for AstraZeneca's future therapies being developed to address chronic diseases.
Under the agreement, QIAGEN will develop and validate a genotyping assay using QIAGEN's syndromic testing platform QIAstat-Dx. The test will enable specialty care providers to potentially perform genotyping whilst patients are undergoing routine clinical examination, thus enabling fast decision making for potential suitability for AstraZeneca's genomically targeted medicines.

QIAGEN Expands Master Collaboration Agreement With AstraZeneca's Future Therapies To Develop And Validate A Genotyping Assay Using Co's Syndromic Testing Platform QIAstat-Dx

Baird analyst Catherine Schulte maintains Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) with a Outperform and raises the price target from $49 to $52.

Price Target

Baird Maintains Outperform on Qiagen, Raises Price Target to $52

QIAGEN has updated its FY 2024 outlook based on the solid core business performance in the first half of the year, which was about $15 million CER above guidance, as well as the decision to phase out the NeuMoDx clinical PCR system. As a result, total net sales are expected to be at least $1.985 billion CER and includes a $30 million CER adjustment in expected NeuMoDx sales for 2024.
The outlook for adjusted diluted EPS has been increased to at least $2.16 CER, while the adjusted operating income margin target is for at least 28.5% compared to 26.9% in 2023.

Guidance

Qiagen Sees FY24 EPS $2.16 Vs $2.12 Est.; Revenue $1.985B Vs $2B Est.

Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.51 by 7.84 percent. This is a 7.84 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $496.00 million which beat the analyst consensus estimate of $494.49 million by 0.31 percent. This is a 0.20 percent increase over sales of $495.00 million the same period last year.

Qiagen Q2 Adj $0.55 Beats $0.51 Estimate, Sales $496.00M Beat $494.49M Estimate

QIAGEN (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>, Frankfurt Prime Standard: QIA)))) today announced a partnership with the Snow Molecular Anthropology Lab at the University of Montana in the fields of human identification and forensics.
The partnership aims to provide forensic services for missing and murdered Indigenous people (MMIP) and unidentified human remains (UHRs) using DNA technologies such as next-generation sequencing (NGS) and forensic investigative genetic genealogy (FIGG).
Within this long-term partnership, QIAGEN supports the Snow Molecular Anthropology Lab with a MiSeq FGx sequencing system, training, ForenSeq Kintelligence kits and the ForenSeq Kintelligence HT System.

QIAGEN Announces Partnership With The Snow Molecular Anthropology Lab At The University Of Montana In The Fields Of Human Identification And Forensics To Enhance The Identification Of Human Remains

QIAGEN N.V.&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/qgen#NYSE">QGEN</a>) recently lauded the new guidelines in the United States that recommend screening at-risk children of all ages for latent tuberculosis (TB) infection with modern blood-based tests such as QuantiFERON-TB Gold Plus (QFT-Plus). The latest guidelines from the American Academy of Pediatrics highlight testing for TB with modern interferon-gamma release assays (IGRAs).
With this development, the company aims for its market-leading QFT-Plus to be a gold standard for blood-based tuberculosis detection for patients of all ages.
<h3>More on the New Guidelines</h3>
The new TB screening guidelines build upon AAP&#39;s previous IGRA recommendations and now cover children of all ages, including infants and children aged two and below. The contagious bacterial infection spread primarily through coughing by patients with the active pulmonary form of the disease. As per the CDC (Centers for Disease Control and Prevention) data, TB cases have been rising post-COVID-19 as public health authorities and primary care providers catch up to the &quot;surveillance gap&quot; caused by the pandemic.
An estimated 13 million people in the United States are likely to have latent TB infections, and children are at increased risk for progression from infection to contagious active TB disease. They are also frequently exposed to settings with a higher risk for TB transmission, such as schools and childcare centers. The AAP&#39;s recommendations follow recently updated guidelines from the American College Health Association stating that IGRAs are preferred over the 120-year-old tuberculin skin test&nbsp;for most situations relevant to college health.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ee/69828.jpg?v=1631716656" /> 
Image Source: Zacks Investment Research
The updated childhood TB screening guidelines come as U.S. authorities are expanding the role of latent TB screening in national tuberculosis control efforts. QIAGEN recently partnered with the International Panel Physicians Association to support and educate panel physicians worldwide on new US CDC tuberculosis screening guidelines that require the use of IGRA tests to ensure a safe immigration process, supporting the global fight against TB.
<h3>Significance of QFT-Plus</h3>
Recognized as the world&#39;s leading IGRA blood test, QFT-Plus has been established as a superior alternative to the dated TST. The latter is effective in identifying TB infection in people who have received BCG vaccination, which is common for patients from high-TB-burden countries and those unlikely to return for TST interpretation.
The test has helped patients and providers globally by reducing the number of visits to a single blood draw with a faster turnaround time. Nearly 70-80 million TB skin tests are performed globally each year, including 16-18 million in the United States, with healthcare providers increasingly adopting modern IGRA tests. The expanded AAP recommendations will improve TB infection detection in young children so that they can benefit from preventive treatment, underscoring the importance of the QFT-Plus test.
<h3>Industry Prospects</h3>
Per a Research report, the global TB Diagnostics market was valued at $2.28 billion in 2022 and is likely to witness a 5.2% CAGR through 2022.
TB has emerged as one of the biggest concerns among the government and healthcare agencies, with significant investments being made to develop effective diagnostic technologies to improve patient outcomes and accuracy.
<h3>Notable Developments</h3>
This month, QIAGEN launched 35 new wet-lab tested digital PCR Microbial DNA Detection Assays for its digital PCR platform QIAcuity, significantly broadening its offerings in the field of microbial research. The new assays target a wide range of pathogens responsible for tropical diseases, sexually transmitted infections and urinary tract infections, further solidifying QIAGEN&#39;s position as a leader in microbial detection and analysis.
<h3>Price Performance</h3>
In the past year, QGEN shares have declined 10.5% compared with the industry&#39;s 7.8% fall.
<h3>Zacks Rank and Key Picks</h3>
QIAGEN currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Hims &amp; Hers Health (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hims#NYSE">HIMS</a>), ResMed (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rmd#NYSE">RMD</a>) and Medpace (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/medp#NASDAQ">MEDP</a>). While Hims &amp; Hers Health sports a Zacks Rank #1 (Strong Buy), ResMed and Medpace carry a Zacks Rank #2 (Buy) each at present.
Hims &amp; Hers Heath shares have surged 136.4% in the past year. Estimates for the company&#39;s earnings have increased from 18 cents to 19 cents in 2024 and from 33 cents to 35 cents in 2025 in the past 30 days.
HIMS&#39; earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 79.2%. In the last reported quarter, it posted an earnings surprise of a staggering 150%.
Estimates for ResMed&#39;s fiscal 2024 earnings per share have remained constant at $7.70 in the past 30 days. Shares of the company have plunged 10.8% in the past year compared with the industry&#39;s decline of 2%.
RMD&#39;s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.8%. In the last reported quarter, it delivered an earnings surprise of 10.9%.
Estimates for Medpace&#39;s 2024 earnings per share have remained constant at $11.29 in the past 30 days. Shares of the company have surged 85.2% in the past year compared with the industry&#39;s 5.1% growth.
MEDP&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 12.8%. In the last reported quarter, it delivered an earnings surprise of 30.6%.
<a href="https://www.zacks.com/stock/news/2294797/qiagen-qgen-backs-new-aap-guidelines-supporting-qft-plus-test?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2294797">To read this article on Zacks.com click here.</a>

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MEDP

QIAGEN Backs New AAP Guidelines Supporting QFT-Plus Test

Wolfe Research analyst Doug Schenkel upgrades Qiagen (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QGEN#NYSE">QGEN</a>) from Peer Perform to Outperform and announces $50 price target.

Upgrades

Wolfe Research Upgrades Qiagen to Outperform, Announces $50 Price Target

Qiagen (QGEN) has released an update. Qiagen N.V. reported a steady second quarter in 2024 with net sales of $496 million, a 1% increase at constan...

Qiagen Exceeds Q2 Outlook, Raises Full-Year Forecast

Qiagen (QGEN) has released an update. Qiagen's financial health shows a decrease in total assets from $6.115 billion at the end of 2023 to $5.584 b...

Qiagen Reports Decrease in Total Assets Mid-2024

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Qiagen (QGEN) has released an update. Qiagen N.V. has announced a private placement of senior, unsecured convertible bonds totaling $450 million, a...

Qiagen Launches $450 Million Convertible Bond Offering

Qiagen (QGEN) has released an update. Qiagen N.V. has set the terms for new senior unsecured convertible bonds due in 2031, with an aggregate princ...

Qiagen Announces Terms for $500M Convertible Bonds

QIAGEN, Lilly to develop Alzheimer's risk detection test

Stock Splits Continue Their 2024 Comeback

Goldman sees a 'relief rally' potential for these option calls ahead of earnings

Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Respiratory Panel Mini test for clinical use. It is the third test to receive FDA c...

Qiagen announces FDA clearance of QIAstat-Dx Respiratory Panel Mini test

Qiagen (QGEN) announced that the FDA has cleared the QIAstat-Dx Meningitis/Encephalitis Panel for clinical use. This marks the fourth QIAstat-Dx sy...

Comments

Qiagen

매도 수량

Qiagen (NYSE:QGEN) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌